MX362454B - Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos. - Google Patents

Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos.

Info

Publication number
MX362454B
MX362454B MX2014013568A MX2014013568A MX362454B MX 362454 B MX362454 B MX 362454B MX 2014013568 A MX2014013568 A MX 2014013568A MX 2014013568 A MX2014013568 A MX 2014013568A MX 362454 B MX362454 B MX 362454B
Authority
MX
Mexico
Prior art keywords
binding
antibodies capable
activated form
form factor
coagulation factor
Prior art date
Application number
MX2014013568A
Other languages
English (en)
Other versions
MX2014013568A (es
Inventor
Martina Schäfer
Christoph Gerdes
Anja Buchmüller
Ricarda Finnern
Frank Dittmer
Hannah Jörissen
Andreas Wilmen
Joanna Grudzinska-Goebel
Asako Itakura
Leung Philberta Y
Erik Tucker
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2014013568A publication Critical patent/MX2014013568A/es
Publication of MX362454B publication Critical patent/MX362454B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos capaces de unirse con el factor Xl de coagulación y/o a su forma activada, factor Xla, y a sus procedimientos de uso, en particular procedimientos de uso como agentes que inhiben la agregación plaquetaria y, así, inhiben la formación de trombos.
MX2014013568A 2012-05-10 2013-05-08 Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos. MX362454B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12167438 2012-05-10
EP12181697 2012-08-24
EP13150361 2013-01-07
US201361817675P 2013-04-30 2013-04-30
PCT/EP2013/059618 WO2013167669A1 (en) 2012-05-10 2013-05-08 Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

Publications (2)

Publication Number Publication Date
MX2014013568A MX2014013568A (es) 2014-12-08
MX362454B true MX362454B (es) 2019-01-18

Family

ID=49550177

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013568A MX362454B (es) 2012-05-10 2013-05-08 Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos.

Country Status (24)

Country Link
US (4) US9783614B2 (es)
EP (2) EP2847228B1 (es)
JP (2) JP6348900B2 (es)
KR (1) KR102060376B1 (es)
CN (1) CN104684932B (es)
AR (1) AR091024A1 (es)
AU (2) AU2013258043B2 (es)
BR (1) BR112014027952B1 (es)
CA (1) CA2872926C (es)
DK (1) DK2847228T3 (es)
ES (1) ES2698950T3 (es)
HR (1) HRP20181680T1 (es)
HU (1) HUE040580T2 (es)
IL (1) IL235238B (es)
LT (1) LT2847228T (es)
MX (1) MX362454B (es)
NZ (1) NZ701121A (es)
PL (1) PL2847228T3 (es)
RS (1) RS57889B1 (es)
SG (2) SG11201406719UA (es)
SI (1) SI2847228T1 (es)
TW (2) TWI644925B (es)
WO (1) WO2013167669A1 (es)
ZA (1) ZA201407784B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566963T3 (es) 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
TR201904662T4 (tr) 2008-12-18 2019-05-21 Gruber Andras Anti-fxı antikorları ve kullanma yöntemleri.
IN2014CN02805A (es) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
CN103974938B (zh) 2011-10-14 2016-11-09 百时美施贵宝公司 作为因子xia抑制剂的经取代的四氢异喹啉化合物
EP2847228B1 (en) * 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
JP6154473B2 (ja) 2012-10-12 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤の結晶形
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
NO2760821T3 (es) 2014-01-31 2018-03-10
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
PT3177642T (pt) 2014-08-07 2022-02-14 Novartis Ag Anticorpos semelhantes a angiopoietina 4 e métodos de uso
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
IL253180B2 (en) 2015-01-02 2023-04-01 Dyax Corp Bispecific antibodies against plasma kallikrein and factor xii
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
KR102794955B1 (ko) 2015-07-21 2025-04-15 다케다 파머수티컬 컴패니 리미티드 Xiia 인자의 단일클론 항체 저해제
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
BR112018014810A2 (pt) 2016-01-22 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-fator xi de coagulação
CN109153726A (zh) * 2016-03-23 2019-01-04 普希克斯私人有限公司 抗因子xi的活性位点的单克隆抗体及其用途
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CN116425879A (zh) 2016-06-14 2023-07-14 默沙东有限责任公司 抗-凝血因子xi抗体
CN110099927A (zh) * 2016-09-20 2019-08-06 拜耳医药股份公司 对抗xi因子的新型抗体及其用途
WO2018089248A2 (en) * 2016-11-02 2018-05-17 Tucker Erik L E-we thrombin analog and fibrinolytic combination
KR102702288B1 (ko) * 2016-12-23 2024-09-05 노파르티스 아게 항-인자 XI/XIa 항체를 사용한 치료 방법
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
PL3570882T3 (pl) * 2017-01-19 2022-02-07 Bayer Pharma Aktiengesellschaft Nowa stabilna formulacja dla przeciwciał fxia
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
CA3083210A1 (en) * 2017-11-22 2018-11-20 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
US20210292434A1 (en) 2018-07-05 2021-09-23 Bayer Aktiengesellschaft NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIa ANTIBODIES
CN112513096B (zh) * 2018-08-01 2023-08-25 诺和诺德股份有限公司 改进的促凝血抗体
ES3016309T3 (en) 2018-08-07 2025-05-08 Nippon Telegraph & Telephone Optical transport system
BR112021002472A2 (pt) * 2018-08-09 2021-07-27 Shanghai Benemae Pharmaceutical Corporation anticorpos antifator xi
CA3113691A1 (en) 2018-09-17 2020-03-26 Board Of Regents, The University Of Texas System Compositions and methods for treating bone injury
US20210395390A1 (en) 2018-10-31 2021-12-23 Bayer Aktiengesellschaft Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
CN113474373B (zh) * 2019-01-21 2025-09-02 阿罗诺拉股份有限公司 具有抗血栓形成和抗炎作用的新型抗因子xi人源化抗体及其用途
JP7650807B2 (ja) 2019-04-16 2025-03-25 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ＦＸＩ／ＦＸＩａ抗体及びその使用
CN110423278B (zh) 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
US20230220111A1 (en) * 2020-07-02 2023-07-13 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN120858120A (zh) * 2022-12-30 2025-10-28 甘李药业股份有限公司 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途
CN119454938B (zh) * 2024-11-15 2025-07-25 广州骐骥生物科技有限公司 一种枸橼酸透析浓缩液及其制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US20030235587A1 (en) 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
ID22176A (id) 1996-10-14 1999-09-09 Bayer Ag Turunan pirazola tersubstitusi-heterosiklilmetil yang baru
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
WO2003013423A2 (en) 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
US20080138837A1 (en) 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7279513B2 (en) 2004-11-19 2007-10-09 Nalco Company Preparation of neutralized ethylene-acrylic acid polymer dispersions and use in printing media for improvement of digital toner adhesion
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
HRP20140081T1 (hr) 2006-08-18 2014-03-28 Novartis Ag Prlr-specifiäśna antitijela i njihova uporaba
MX2009011500A (es) 2007-04-23 2010-01-29 Schering Corp Anticuerpos anti-mdl-1.
US8574849B2 (en) 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
ES2566963T3 (es) 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
US20110159006A1 (en) * 2008-06-19 2011-06-30 Erik Hack Use of anti-factor xi antibodies for prevention of thrombus formation
WO2010065275A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
TR201904662T4 (tr) * 2008-12-18 2019-05-21 Gruber Andras Anti-fxı antikorları ve kullanma yöntemleri.
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
EP2575473B1 (en) 2010-05-27 2016-01-20 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US20130158028A1 (en) 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
PH12013500055A1 (en) 2010-07-09 2017-08-23 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
ES2583086T3 (es) 2011-04-21 2016-09-19 Bayer Intellectual Property Gmbh Pirazolopiridinas sustituidas con fluoroalquilo y su uso
EP2705037B1 (de) 2011-05-06 2016-06-22 Bayer Intellectual Property GmbH Substituierte imidazopyridine und imidazopyridazine und ihre verwendung
EP2763990B1 (en) 2011-09-01 2017-02-22 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
MX348470B (es) 2011-09-02 2017-06-13 Bayer Ip Gmbh Pirimidinas anilladas sustituidas y uso de las mismas.
EP2847228B1 (en) * 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

Also Published As

Publication number Publication date
AU2013258043B2 (en) 2017-11-30
WO2013167669A1 (en) 2013-11-14
SG10201609322QA (en) 2017-01-27
KR20150008166A (ko) 2015-01-21
AU2018200850C1 (en) 2020-03-12
CA2872926A1 (en) 2013-11-14
HRP20181680T1 (hr) 2018-12-14
TW201400504A (zh) 2014-01-01
US10221247B2 (en) 2019-03-05
IL235238A0 (en) 2014-12-31
RS57889B1 (sr) 2019-01-31
TWI631140B (zh) 2018-08-01
SI2847228T1 (sl) 2018-11-30
KR102060376B1 (ko) 2019-12-30
AU2018200850B2 (en) 2019-09-19
JP2018148920A (ja) 2018-09-27
HUE040580T2 (hu) 2019-03-28
AU2018200850A1 (en) 2018-02-22
AR091024A1 (es) 2014-12-30
IL235238B (en) 2019-08-29
CN104684932A (zh) 2015-06-03
LT2847228T (lt) 2018-11-12
HK1207091A1 (en) 2016-01-22
AU2013258043A1 (en) 2014-11-13
US20150099298A1 (en) 2015-04-09
SG11201406719UA (en) 2014-11-27
ZA201407784B (en) 2019-01-30
JP6348900B2 (ja) 2018-06-27
DK2847228T3 (en) 2018-11-19
US20180051093A1 (en) 2018-02-22
ES2698950T3 (es) 2019-02-06
TWI644925B (zh) 2018-12-21
BR112014027952A2 (pt) 2019-07-09
US20180112009A1 (en) 2018-04-26
EP3404045A1 (en) 2018-11-21
US9783614B2 (en) 2017-10-10
BR112014027952B1 (pt) 2022-06-21
US10040866B2 (en) 2018-08-07
US20190284300A1 (en) 2019-09-19
CA2872926C (en) 2022-07-05
MX2014013568A (es) 2014-12-08
JP2015517305A (ja) 2015-06-22
TW201811834A (zh) 2018-04-01
NZ701121A (en) 2017-06-30
US11046783B2 (en) 2021-06-29
PL2847228T3 (pl) 2019-03-29
CN104684932B (zh) 2019-03-12
EP2847228B1 (en) 2018-07-25
EP2847228A1 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
NZ701121A (en) Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2012140274A3 (en) Agonists and antagonists of the wnt pathway
MX362582B (es) Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa.
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
TN2012000366A1 (en) Anticoagulant antidotes
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
UA117011C2 (uk) Фармацевтичний склад омекамтиву мекарбілу і спосіб його застосування
MX382540B (es) Proteinas de fusion para inhibir la angiogenesis
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
WO2012050611A3 (en) Aptamers to glycoprotein vi
MY179243A (en) Supplemented fish feed
MX345926B (es) Nuevas composiciones, producción de las mismas y uso de las mismas para la producción de poliamidas coladas.
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
WO2013190274A3 (en) Biodegradable compositions
MX2016014416A (es) Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
UA116207C2 (uk) Виділена тверда форма моногідрохлориду анамореліну та фармацевтична композиція, що її містить
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX354501B (es) Ingrediente perfumante de la familia galbano.
CY1120786T1 (el) Αντισωματα ικανα να δεσμευονται στον παραγοντα πηξης xi και/ή στην ενεργοποιημενη μορφη αυτου, τον παραγοντα χια, και χρησεις αυτων
SG10201807066UA (en) Peptides and methods of use
HK1231933A1 (en) Aptamer construct
IN2013CH00453A (es)

Legal Events

Date Code Title Description
FG Grant or registration